Superb! KKU lecturer-researcher is the only one in Thailand to receive the 2022 CCF Research Fellowship Awards

The Cholangiocarcinoma Foundation (CCF) in the USA was founded by a family who lost a loved one to cholangiocarcinoma in 2006 in Salt Lake City, Utah State of the United States Since then, CCA Foundation USA has continued to grow into a leading global organization for research, education, and social awareness about cholangiocarcinoma. and has a mission to find a cure and improve the quality of life of cholangiocarcinoma patients

The primary focus of the CCA Foundation USA is the discovery of diagnostic tests. and new treatment guidelines for cholangiocarcinoma which the Foundation There is a philosophy that effective treatment and care for cholangiocarcinoma patients must come from 1) intensive basic research that will lead to building a body of knowledge and understanding about cancer. and 2) Innovative research leading to the development of new diagnostic methods. and the discovery of drugs for effective treatment of cholangiocarcinoma. Since 2015, the Foundation has awarded more than $2 million (approximately 64 million baht) to support research. Innovative with high quality and to promote collaboration among cholangiocarcinoma researchers This year, 47 researchers in cholangiocarcinoma from 12 countries around the world (Australia, Canada, France, Germany, Italy, South Korea, Netherlands, Spain, Turkey, United Kingdom, United States and Thailand) submitted Letter of Intent (LOI) to participate in the competition. The 2022 CCF Research Fellowship is awarded and only 24 projects have progressed to the second round of selection. The committee of 17 qualified members consisted of doctors. and scientists with experience and expertise in cholangiocarcinoma including supporting research in cholangiocarcinoma A total of 11 research project proposals were assessed and selected the highest quality research projects for this year’s award. The Cholangiocarcinoma Foundation USA will announce the shortlisted researchers for the 2022 Cholangiocarcinoma Foundation Research Fellowship at The 2022 CCF Annual Conference, between 23 – 25 February 2022

On February 25, 2022, at 3:30 p.m. (Utah local time) at the U.S. CCF Foundation 2022 Symposium, Dr. Katie Kelly, Chair of the Board of Trustees, decided on the 2022 CCF Research Fellowship Award. Announcing the list of 11 award-winning researchers, consisting of:

  1. Dr. Marina Barcena-Varela from the Icahn School of Medicine at Mount Sinai, USA.
  2. Dr. Srinadh Choppara, University of Michigan, USA
  3. Dr. Michael Lidsky from Duke University, USA
  4. Dr. Cecilia Monge, NIH/National Cancer Institute, USA
  5. Dr. Evan O’Loughlin, Massachusetts General Hospital Cancer Center/Harvard Medical School, USA
  6. Dr. Jutarop Phetcharaburanin from Khon Kaen University, Thailand
  7. Dr. Rutger-Jan Swijnenburg, Amsterdam UMC Institute, The Netherlands
  8. Dr. Alessandro Gambella, UPMC Montefiore Institute, USA
  9. Dr. Kishor Pant, Regents Institute of the University of Minnesota, USA
  10. Dr. Vindhya Vijay, Massachusetts General Hospital Cancer Center/Harvard Medical School, USA
  11. Dr. Daniel Zabransky, Johns Hopkins School of Medicine, USA
 

 

The only one in Thailand to receive the 2022 CCF Research Fellowship Awards

One of the researchers selected for this year’s award is Dr. Jutarop Phetcharaburanin, lecturer at the Department of Biochemistry, Faculty of Medicine, and researcher under the Cholangiocarcinoma Research Institute Khon Kaen University. He is the only Thai researcher to be selected for this award in 2022.

Dr. Jutarop Phetcharaburanin, MBBS, PhD

Dr. Jutarop Phetcharaburanin holds a doctorate in Clinical Medicine Research (Computational and Systems Medicine) from Imperial College London, England, which is an educational institution ranked 7th in the QS World University Ranking in the world (Data in 2022). The professor has expertise in the use of research methodology. Computational and Systems Medicine to study the relationship between intestinal bacteria and the human body in molecular signaling between cholangiocarcinoma with Omics Science.